The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database

Molecular testing has become important in the biomarker program of clinical trials for advanced non-small lung cancer (NSCLC). These tissue samples often have to be analyzed in a central laboratory. We evaluated the turnaround time and possible delay in start of therapy in this process and how often testing resulted in inclusion in a clinical trial.publisher: Elsevier articletitle: The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database journaltitle: Lung Cancer articlelink: http://dx.doi.org/10.1016/j.lungcan.2016.11.003 content_type: article copyright: © 2016 Elsevier Ireland Ltd. All rights reserved.status: publishe